Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: A prospective study

Neuro-Oncology

Volumn 18, Issue 3, 2016, Pages 435-444

  Habets, Esther J J ^a   Dirven, Linda ^b   Wiggenraad, Ruud G ^c   Verbeek De Kanter, Antoinette ^c   Lycklama À Nijeholt, Geert J ^a   Zwinkels, Hanneke ^a   Klein, Martin ^b   Taphoorn, Martin J B ^a,b  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Radiotherapy Center West   (Netherlands)

Author keywords

brain metastases; cognition; health related quality of life; stereotactic radiotherapy

Indexed keywords

CORTICOSTEROID;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COGNITION; EXECUTIVE FUNCTION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; STEREOTACTIC RADIOTHERAPY; STEREOTACTIC TREATMENT; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; AGED; BRAIN NEOPLASMS; HEALTH STATUS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COGNITION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84960082203     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov186     Document Type: Article

References (51)

1. Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10): 2698-2705.
2. Barnholtz-Sloan JS, Yu C, Sloan AE, et al. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol. 2012;14(7):910-918.
3. Kaal EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol. 2005;4(5):289-298.
4. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22(1):157-165.
5. Chang EL, Wefel JS, Maor MH, et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery. 2007;60(2):277-283.
6. Kondziolka D, Niranjan A, Flickinger JC, et al. Radiosurgery with or without whole-brain radiotherapy for brain metastases: The patients' perspective regarding complications. Am J Clin Oncol. 2005;28(2):173-179.
7. Jyothirmayi R, Saran FH, Jalali R, et al. Stereotactic radiotherapy for solitary brain metastases. Clin Oncol (R Coll Radiol). 2001; 13(3):228-234.
8. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419-425.
9. Lin NU, Wefel JS, Lee EQ, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013;14(10):e407-e416.
10. Lippitz B, Lindquist C, Paddick I, et al. Stereotactic radiosurgery in the treatment of brain metastases: The current evidence. Cancer Treat Rev. 2014;40(1):48-59.
11. Tsao M, Xu W, Sahgal A. A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer. 2012;118(9):2486-2493.
12. Platta CS, Khuntia D, Mehta MP, et al. Current treatment strategies for brain metastasis and complications from therapeutic techniques: A review of current literature. Am J Clin Oncol. 2010; 33(4):398-407.
13. Mehta MP, Tsao MN, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63(1):37-46.
14. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141.
15. Regine WF, Scott C, Murray K, et al. Neurocognitive outcome in brain metastases patients treated with acceleratedfractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys. 2001;51(3):711-717.
16. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68(5):1388-1395.
17. Cole AM, Scherwath A, Ernst G, et al. Self-reported cognitive outcomes in patients with brain metastases before and after radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(4): 705-712.
18. Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65-72.
19. Steinmann D, Paelecke-Habermann Y, Geinitz H, et al. Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer. 2012; 12:283.
20. Caissie A, Nguyen J, Chen E, et al. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys. 2012;83(4):1238-1245.
21. Lin NU, Lee EQ, Aoyama H, et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013;14(10):e396-e406.
22. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-1459.
23. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. New York: Oxford Univerity Press; 2004.
24. Meyers CA, Cantor SB. Neuropsychological assessment and treatment of patients with malignant brain tumors. In: Prigatano GP, Pliskin NH, eds. Clinical Neuropsychology and Cost Outcome Research, a Beginning. New York: Psychology Press, Inc.; 2003: 159-173.
25. Tucha O, Smely C, Preier M, et al. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47(2):324-333.
26. Jolles J, Van Boxtel MP, Ponds RW, et al. [The Maastricht aging study (MAAS). The longitudinal perspective of cognitive aging]. Tijdschr Gerontol Geriatr. 1998;29(3):120-129.
27. Van der ElstW. The Neuropsychometrics of Aging: Normative Studies in the Maastricht Aging Study. Maastricht: Neuropsy publishers; 2006.
28. De Bie SE. [Proposal for uniformisation of questions regarding background variables and interviews]. Leiden: Leiden University Press; 1987.
29. Fastenau PS, Denburg NL, Hufford BJ. Adult norms for the Rey-Osterrieth Complex Figure Test and for supplemental recognition and matching trials from the Extended Complex Figure Test. Clin Neuropsychol. 1999;13(1):30-47.
30. Kessels RP, van den Berg E, Ruis C, et al. The backward span of the Corsi Block-Tapping Task and its association with the WAIS-III Digit Span. Assessment. 2008;15(4):426-434.
31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
32. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5(1):139-150.
33. van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer. 2011;47(5):667-675.
34. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123.
35. Mathiowetz V, Matuska KM, Murphy ME. Efficacy of an energy conservation course for persons with multiple sclerosis. Arch Phys Med Rehabil. 2001;82(4):449-456.
36. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA. 2006;295(21):2483-2491.
37. Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002;53(3):519-526.
38. Gerstenecker A, Nabors LB, Meneses K, et al. Cognition in patients with newly diagnosed brain metastasis: profiles and implications. J Neurooncol. 2014;120(1):179-185.
39. Chang EL,Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol. 2009;10(11):1037-1044.
40. Onodera S, Aoyama H, Tha KK, et al. The value of 4-month neurocognitive function as an endpoint in brain metastases trials. J Neurooncol. 2014;120(2):311-319.
41. Minniti G, Esposito V, Clarke E, et al. Stereotactic radiosurgery in elderly patients with brain metastases. J Neurooncol. 2013; 111(3):319-325.
42. Kirkpatrick JP, Wang Z, Sampson JH, et al. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brainmetastases: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2015;91(1):100-108.
43. Steinvorth S, Wenz F, Wildermuth S, et al. Cognitive function in patients with cerebral arteriovenous malformations after radiosurgery: prospective long-term follow-up. Int J Radiat Oncol Biol Phys. 2002;54(5):1430-1437.
44. Brown PD, Asher AL, Ballman KV, et al. NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiotherapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases [abstract]. J Clin Oncol. 2015;33(suppl; LBA4).
45. Meyers CA,Wefel JS. The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21(19):3557-3558.
46. Bosma I, Reijneveld JC, Douw L, et al. Health-related quality of life of long-term high-grade glioma survivors. Neuro Oncol. 2009; 11(1):51-58.
47. Schmand B, Lindeboom J, Van Harskamp F. [The 15 words test A and B (a preliminary manual)]. Groningen: Afdeling Neuropyschologie, AZG; 1992.
48. Osterreith PA. Le test de copie d'une figure complexe [A test regarding a complex figure]. Arch Psychologie. 1944;30: 206-356.
49. Wechsler D. Wechsler Adult Intelligence Scale III [Dutch revision. Technical manual]. Lisse: Swets Test Publishers; 2000.
50. Van der ElstW, Van Boxtel MP, Van Breukelen GJ, et al. The Concept Shifting Test: adult normative data. Psychol Assess. 2006;18(4): 424-432.
51. Krabbendam L, Kalff AC. The Behavioural Assessment of the Dysexecutive Syndrome: Dutch version. Lisse: Swets and Zeitlinger; 1998.